Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 10;76(19):2267-2281.
doi: 10.1016/j.jacc.2020.08.079.

Cardio-Oncology Education and Training: JACC Council Perspectives

Affiliations
Review

Cardio-Oncology Education and Training: JACC Council Perspectives

Jose A Alvarez-Cardona et al. J Am Coll Cardiol. .

Abstract

The innovative development of cancer therapies has led to an unprecedented improvement in survival outcomes and a wide array of treatment-related toxicities, including those that are cardiovascular in nature. Aging of the population further adds to the number of patients being treated for cancer, especially those with comorbidities. Such pre-existing and developing cardiovascular diseases pose some of the greatest risks of morbidity and mortality in patients with cancer. Addressing the complex cardiovascular needs of these patients has become increasingly important, resulting in an imperative for an intersecting discipline: cardio-oncology. Over the past decade, there has been a remarkable rise of cardio-oncology clinics and service lines. This development, however, has occurred in a vacuum of standard practice and training guidelines, although these are being actively pursued. In this council perspective document, the authors delineate the scope of practice in cardio-oncology and the proposed training requirements, as well as the necessary core competencies. This document also serves as a roadmap toward confirming cardio-oncology as a subspecialty in medicine.

Keywords: cancer; cardio-oncology; cardiotoxicity; training.

PubMed Disclaimer

Conflict of interest statement

Author Relationship With Industry Dr. Zaha is supported by The Cancer Prevention Research Institute of Texas award RP18040. Dr. Mitchell is supported by the Children’s Discovery Institute and Longer Life Foundation. Dr. Herrmann is supported by the National Institutes of Health/National Cancer Institute grant R01CA233601 and the Miami/Florida Heart Research Foundation. Dr. Mitchell has received research funds from Pfizer. Dr. Barac has been on the advisory board of Takeda Ariad Pharmaceuticals. Dr. Dent has grant funding from Novartis US; and has received consultant fees from Novartis Canada. Dr. Lenihan has been a consultant to Lilly, Acorda, Bristol Myers Squibb, and Roche; and has received research funding from Myocardial Solutions. Dr. Herrmann has been a consultant to Amgen, Bristol Myers Squibb, and Takeda (Ariad) Pharmaceuticals. None of these are directly related to the current work.

Figures

FIGURE 1
FIGURE 1. Cardio-Oncology as the Integration of Cardiology and Oncology/Hematology
The specialty of cardio-oncology can be considered as the blend of both cardiology and oncology/hematology, with the large diversity in disease entities and subspecialty aspects, as illustrated.
FIGURE 2
FIGURE 2. Road to Cardio-Oncology Based on Prior Training Track
Both cardiology and hematology/oncology fellows are eligible for training in cardio-oncology. Their training needs, however, differ, emphasizing the learning of the knowledge of their counterpart discipline. CT = computed tomography; CV = cardiovascular; ECG = electrocardiography; MRI = magnetic resonance imaging.
CENTRAL ILLUSTRATION
CENTRAL ILLUSTRATION. Central Elements of Cardio-Oncology Training
Cardiology and hematology/oncology trainees or specialists can aspire to different levels of cardio-oncology training and acquire core knowledge elements and core competencies as outlined in an environment that provides the appropriate learning environment.

References

    1. McCune JS. Rapid advances in immunotherapy to treat cancer. Clin Pharmacol Ther 2018;103: 540–4. - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34. - PubMed
    1. Sturgeon KM, Deng L, Bluethmann SM, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J 2019;40:3889–97. - PMC - PubMed
    1. Lenihan DJ, Cardinale D, Cipolla CM. The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society. Prog Cardiovasc Dis 2010; 53:88–93. - PubMed
    1. Bhatt DL. Birth and maturation of cardio-oncology. J Am Coll Cardiol CardioOnc 2019;1:3. - PMC - PubMed

Publication types